This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Nichi-Iko Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Key information

-87.4%

Earnings growth rate

-86.8%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	2.6%
Return on equity	n/a
Net Margin	-87.7%
Last Earnings Update	31 Dec 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Nichi-Iko Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:NHKF.F Revenue, expenses and earnings (JPY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 22	182,880	-160,439	29,073	4,772
30 Sep 22	184,379	-145,208	28,125	4,655
30 Jun 22	183,179	-105,407	27,867	5,173
31 Mar 22	179,060	-104,984	27,879	4,248
31 Dec 21	184,265	-19,667	27,116	4,029
30 Sep 21	184,518	-18,918	27,438	4,275
30 Jun 21	185,896	-8,246	27,196	4,349
31 Mar 21	188,218	-4,179	27,029	4,335
31 Dec 20	186,759	-606	26,589	4,246
30 Sep 20	188,188	2,273	25,708	4,040
30 Jun 20	188,818	3,610	25,628	3,749
31 Mar 20	190,076	5,133	25,614	4,261
31 Dec 19	181,530	5,482	24,173	3,859
30 Sep 19	175,765	5,250	23,869	3,688
30 Jun 19	170,837	6,216	23,333	3,571
31 Mar 19	166,592	6,864	22,504	3,503
31 Dec 18	148,475	9,317	-981	7,065
30 Sep 18	152,766	10,241	7,759	6,382
30 Jun 18	158,482	8,567	15,484	5,687
31 Mar 18	164,717	8,070	23,136	4,467
31 Dec 17	189,563	7,388	46,047	7,263
30 Sep 17	182,518	5,059	43,855	7,263
30 Jun 17	173,856	4,752	42,584	7,263
31 Mar 17	163,372	4,788	40,112	7,263
31 Dec 16	152,468	3,647	40,882	4,874
30 Sep 16	149,677	9,595	38,837	4,874
30 Jun 16	146,493	10,736	36,631	4,874

Quality Earnings: NHKF.F is currently unprofitable.

Growing Profit Margin: NHKF.F is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NHKF.F is unprofitable, and losses have increased over the past 5 years at a rate of 87.4% per year.

Accelerating Growth: Unable to compare NHKF.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NHKF.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.6%).

Return on Equity

High ROE: NHKF.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/04/02 20:57
End of Day Share Price	2023/03/08 00:00
Earnings	2022/12/31
Annual Earnings	2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nichi-Iko Pharmaceutical Co., Ltd. is covered by 14 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Atsushi Seki	Barclays
Hidemaru Yamaguchi	Citigroup Inc
Fumiyoshi Sakai	Credit Suisse